Completed PHASE3 INTERVENTIONAL NCT00084071

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia

Sponsor: Novartis Pharmaceuticals

Conditions Pneumonia

Interventions Tifacogin

Updated 9 times since 2017 Last updated: Dec 11, 2020 Started: May 31, 2004 Primary completion: Jul 31, 2008 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00084071, this PHASE3 trial focuses on Pneumonia and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Oct 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Oct 2020 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Allentown, United States , Argenteuil, France , Atlanta, United States , Baltimore, United States , Bay Pines, United States , Belfort, France , Besançon, France , Bloemfontein, South Africa , Bouge, Belgium and 138 more locations